Leora S. Boussi

Oncology
1275 York Ave
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Journal: Cancer
Published: May 01, 2026

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Journal: Leukemia & lymphoma
Published: March 14, 2026

Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion.

Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion.

Journal: Haematologica
Published: March 12, 2026

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Journal: Haematologica
Published: November 10, 2025

An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.

An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.

Journal: Haematologica
Published: October 24, 2025

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Journal: Blood neoplasia
Published: September 18, 2025

Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.

Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.

Journal: Haematologica
Published: August 07, 2025

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

Journal: Cancer
Published: May 20, 2025

Barriers to Chimeric Antigen Receptor T-Cell Therapy.

Barriers to Chimeric Antigen Receptor T-Cell Therapy.

Journal: JAMA oncology
Published: May 15, 2025

Advances in menin inhibition in acute myeloid leukemia.

Advances in menin inhibition in acute myeloid leukemia.

Journal: Trends in cancer
Published: April 15, 2025

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.

Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.

Journal: British journal of haematology
Published: February 12, 2025

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Journal: Blood advances
Published: November 12, 2024
Showing 1-12 of 28

Last Updated: 09/26/2026